VivoSeq
Immunology

Steroid-Refractory Acute Graft-Versus-Host Disease

0

Pipeline Programs↗

4

Active Trials↗

3

Companies Involved↗

Steroid-Refractory Acute Graft-Versus-Host Disease is an early-stage landscape with 0 programs across 3 companies. The most active players are Incyte, Suzhou Zelgen Biopharmaceuticals Co.,Ltd, Wuhan Optics Valley Vcanbiopharma Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Incyte logo

Incyte

0 programs

PreclinicalS

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

0 programs

PreclinicalW

Wuhan Optics Valley Vcanbiopharma Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Completed2 · 33%
Recruiting2 · 33%
Not yet recruiting2 · 33%

Clinical Trials

Trial Activity

6 trials

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy
Recruiting·Mmedac GmbH·Phase 3·NCT04629833·210 enrolled
Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease
Recruiting·RReAlta Life Sciences, Inc.·Phase 2·NCT06343792·66 enrolled
A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.
Not yet recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT04971551·60 enrolled
A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment
Not yet recruiting·WWuhan Optics Valley Vcanbiopharma Co., Ltd.·Phase 1/2·NCT06677255·149 enrolled
Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease
Completed·AAltruBio Inc.·Phase 1·NCT03327857·37 enrolled
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
Completed·Incyte logoIncyte·Phase 2·NCT02953678·71 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)